CytoDyn: Buy, Sell, Or Hold Following PRO 140 Commercial Agreement [Seeking Alpha]
CYTODYN INC (CYDY)
NASDAQ:AMEX Investor Relations:
ir.cytodyn.com
Company Research
Source: Seeking Alpha
Summary CytoDyn recently announced Vyera Pharmaceuticals as the company's U.S. commercial partner for PRO 140 in HIV indications. As a result, the stock has doubled in value and is now trading north of $1.00 per share. I debate whether to buy, sell, or hold CYDY following the announcement. I review the details of the press release and discuss what I like and don't like about the agreement. CytoDyn Inc. ( OTCQB:CYDY I intend to review the press release and go over the details of the Vyera agreement. In addition, I discuss what I like and what I don’t like about the agreement. Finally, I reveal my plans to add to my undersized CYDY position in 2020. The Details According to the What I Like The financial aspect of the Vyera deal is pretty standard for commercial partnership agreements, but that shouldn’t discount the impact it will have on CytoDyn’s fundamentals. $87.5M in upfront and milestone payments is a big deal for a stock that recently was trading around $200M in market cap… add i
Show less
Read more
Impact Snapshot
Event Time:
CYDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYDY alerts
High impacting CYTODYN INC news events
Weekly update
A roundup of the hottest topics
CYDY
News
- CytoDyn Phase 2 study of leronlimab cleared by FDA [Seeking Alpha]Seeking Alpha
- CytoDyn Announces FDA Clearance of Its Phase II Oncology TrialGlobeNewswire
- CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC LaboratoriesGlobeNewswire
- CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development [Yahoo! Finance]Yahoo! Finance
- CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical DevelopmentGlobeNewswire
CYDY
Sec Filings
- 10/30/24 - Form 4
- 10/30/24 - Form 4
- 10/30/24 - Form 4
- CYDY's page on the SEC website